Brian Druker, MD
Enriched profilePresident, Knight Cancer Group · Oregon Health & Science University
Brian Druker is President, Knight Cancer Group at Oregon Health & Science University. OpenAlex indexes 24,008 publications with 95,799 citations (h-index 135); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 22 Oct 2026
Brian Druker, MD, is President, Knight Cancer Group at Oregon Health & Science University. The public record shows 24,008 publications with 95,799 citations (h-index 135), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 7 companies, 11 NIH-funded awards (1993–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Acute Myeloid Leukemia Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 46 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 496.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Sponsor: OHSU Knight Cancer Institute
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Sponsor: National Cancer Institute (NCI)
- Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Sponsor: OHSU Knight Cancer Institute
Industry payments
Updated 22 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202554 payments$555,495openpaymentsdata.cms.gov ↗
- Blueprint Medicines CorporationProgram year20254 payments$17,794openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75.9%Kinase inhibitor75.9%Gleevec39%Sprycel34%Jakafi27%Part D<11 patientsNervous system
24.1%Barbiturate24.1%Butalbital-Acetaminophen-Caffe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
11 NIH research awards on record, funded 1993–2026 per NIH RePORTER. The latest:
- Architecture and Trajectory of Acquired Resistance to Therapy in AML
Oregon Health & Science University
FY2026$1,308,997U54CA224019 - Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia
Oregon Health & Science University
FY2026$1,168,036U01CA271412 - Translating Improved Pairing and Timing of Drug Combination Strategies
Oregon Health & Science University
FY2026$302,354U54CA224019
Congress activity
Updated 22 Oct 2026
111 congress contributions (2003–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 6499: Targeting BCR-ABL1-independent mechanisms of resistance in chronic myeloid leukemia
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 22 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaArticle5,246 citations2001
- 02Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsArticle4,392 citations2002
- 03Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsArticle3,645 citations1996
- 04
- 05Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaArticle3,493 citations2006
Network
Updated 22 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
ohsu.edu/xd/health/services/cancer/about-us/druker
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Doximity
doximity.com/pub/brian-druker-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
aacr.org/professionals/membership/aacr-academy/fellows/brian-j-druker-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - YouTube
ibiology.org/speakers/brian-druker
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ibiology.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 22 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Internship and Residency in Internal Medicine
Barnes Hospital (Washington University School of Medicine), 1981-1984
1984verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗ - B.A. in Chemistry
University of California, San Diego
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗ - M.D.
University of California, San Diego
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Editorial & leadership roles
journal and society appointments- Senior Editor
Molecular Cancer Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Editorial Board
Blood
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Editorial Board
Cancer Cell
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Editorial Board
OncoTarget
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Editorial Board
Cell Cycle
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Member
American Association for Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Member
American Society of Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗ - Member
National Academy of Sciences
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ohsu.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →portland.acsgala.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- Sjöberg Prize2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thelundreport.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →japanprize.jp ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →laskerfoundation.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Independent Director
Amgen, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amgen.com ↗ - JELD-WEN Chair of Leukemia Research
Oregon Health & Science University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Winthrop, MD
Oregon Health & Science University
Richard Maziarz, MD
Oregon Health & Science University
Wayne Clark, MD
Oregon Health & Science University
Eric Simpson, MD
Oregon Health & Science University
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center